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Abstract 
 
PTEN (phosphatase and tensin homologue deleted on chromosome 10) is well known as a tumour 
suppressor. It’s PI(3,4,5)P3 lipid phosphatase activity is an important counteracting mechanism in 
PI3K (phosphoinositide 3-kinase) signalling. Furthermore, PTEN lies upstream of Akt kinase, a key 
enzyme in insulin signalling regulating glucose uptake and cell growth. Therefore, PTEN has recently 
gained attention as a valuable drug target for the treatment of diabetes, stroke, cardiac infarct and 
fertility. This review summarizes the use of small molecules as PTEN inhibitors. Currently available 
methodologies and techniques for accessing PTEN inhibition in vitro and in cellulo will be discussed. 
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1 Introduction 
 
The phosphatidylinositol (PI) 3-phosphatase PTEN has been initially characterised as tumour 
suppressor gene with a putative tyrosine phosphatase domain [1], but has since then proven to be a 
dual specificity phosphatase having inositol lipids as substrates [2]. PTEN is dephosphorylating 3-
phosphorylated inositol lipids, counteracting the action of PI3 kinases by removing the “second 
messengers” created by the action of growth factors, cytokines and cell survival stimulators [2-4]. 
Chemical intervention tools, such as wortmannin [5], LY294002 [6]  or theophylline [7] facilitated the 
discovery of new chemical inhibitors, with all chemical intervention tools having a tremendous 
impact on the elucidation of the role of PI 3-kinases in disease and cancer development [8, 9]. PTEN 
was discovered much later than the PI 3-kinases, and the first PTEN inhibitors were developed in due 
course a decade ago exploiting the dual specificity nature of the PTEN phosphatase. 
Bisperoxovanadium compounds were known tyrosine phosphatase inhibitors, which showed a 
remarkable potency for PTEN in vitro and in vivo [10]. However, these inhibitors are rather 
promiscuous targeting PTEN in the nanomolar dosage range as well as other phosphatases containing 
the CX5R active site motif, whereas the 2nd generation PTEN inhibitor VO-OHpic is fairly specific 
for PTEN in vitro and in vivo [11]. These vanadium-based PTEN inhibitors are currently employed in 
cellular and animal investigations with some recent applications being listed in Table 1. 
Given its role as a tumour suppressor it is not surprising that PTEN has been implicated as a 
biomarker for certain cancers, in particular those affecting the uterus, brain, skin and prostate [12-14]. 
A complete loss of this enzyme triggers PTEN induced cellular senescence (PICS) via a p53 
dependent mechanism [15]. In contrast, a partial loss of PTEN such as in PTEN (+/-) cells will not be 
sufficient to counteract the elevated PI 3-kinase activities in cancers, but at the same time will fail to 
trigger PICS. The consequence of this is a loss of tumour suppression in cancer cells carrying only 
one active copy of PTEN (haploid insufficiency). Thus, PTEN inhibitors might therefore not just be 
important research tools, but may be the first steps towards a future drug discovery programmes for 
PICS based cancer therapy. 
Taken these observations together it is important to understand how the properties of the PTEN 
inhibitors will affect the determination of PTEN activities in vitro and in vivo. Here, we summarise 
the current experimental knowledge about the application of PTEN inhibitors, with particular 
reference to the choice of substrates and the assay conditions. 
 
2 Measuring PTEN inhibition in vitro 
2.1 Choices of substrates 
PTEN is a dual-specific phosphatase belonging to the family of protein tyrosine phosphatases (PTP) 
due to its signature active site motif CX5R, yet several studies have indicated that PTEN has rather 
poor enzymatic activity towards synthetic peptides and para-Nitrophenylphosphate (pNPP ). It has 
therefore been proposed, that PTEN is unlikely to be a classical PTP utilising protein substrates in 
vivo, with the most likely physiological substrate being PI(3,4,5)P3, a key player in cell growth 
signalling [16]. A comparison of kinetic parameters of PTEN towards various substrates (Table 1) 
reveals a ~3-fold lower KM for PI(3,4,5)P3 and a 10 fold higher Vmax than its soluble headgroup IP4 
and ~800-fold lower Vmax than pNPP, demonstrating that in vitro PI(3,4,5)P3 is as well the preferred 
substrate. Another substrate that has been tested is 3-O-Methylfluorescein phosphate (OMFP), an 
artificial substrate also suitable for phosphatases of the PTP family. The use of OMFP over pNPP has 
two advantages. Firstly, OMFP can be used both as a fluorogenic or colorimetric substrate, whereby 
the fluorescence detection is preferred due to higher sensitivity. Secondly, PTEN shows a ~100 times 
higher affinity towards OMFP (KM of 216 ± 14 µM) as compared to pNPP (KM of 25.6 mM).  
While it is apparent that the substrate of choice for PTEN inhibition studies is PI(3,4,5)P3, OMFP is a 
reliable substrate alternative for PTEN inhibition studies [37], which has the advantage of 
continuously monitoring the progress of the enzyme activity. In contrast, the PI(3,4,5)3 assay is an 
endpoint determination of the phosphate released by the enzymatic activity of PTEN. OMFP is 
therefore suitable for high-throughput screening of compound libraries, which can be complemented 
with assays employing the physiological substrate PI(3,4,5)P3 in order to validate any hits. 
  
 
2.2 PTEN inhibition assay 
As mentioned above, PI(3,4,5)3 is the substrate of choice when determining PTEN activities, but it is 
also more cumbersome than assaying PTEN using OMFP. To measure PTEN activity using PI(3,4,5)3 
as a substrate the release of inorganic phosphate will be determined by adding molybdate under strong 
acidic conditions (section 4.1), which also denature the enzyme and thus terminate the reaction 
(endpoint assay). The resulting complex of phosphomolybdate can react with malachite green creating 
a corresponding colour change. Lipid substrates like PI(3,4,5)3 or other phosphoinositide can be 
presented as mixed lipid-detergent micelles, with Octyl β-D-glucopyranoside (OG) being a good 
choice due to its low trace amounts of phosphate. The latter is an important consideration, as some 
detergents will create considerable backgrounds that impact on the overall suitability of the assay.  
 
As previously mentioned (see Table 1), several vanadium based compounds are currently used to 
inhibit PTEN.  The two main groups of PTEN inhibitors consist of bisperoxovanadium (V) 
compounds with various ligands and VO-OHpic with vanadium in the oxidation state of IV which 
were tested for their selectively. Kinetic analysis in the presence of bpVpic (vanadium V) and VO-
OHpic were studied using the enzymes PTEN, PTP1B and SopB, which contain the signature motif 
CX5R characteristic of the PTP family. Although sharing the same active site motif, each enzyme has 
a unique substrate preference. PTP1B for example, described in the literature as valuable type 2 
diabetes target, is a classical PTP acting on proteinaceous substrates [17]. SopB on the other hand, is a 
bacterial virulence factor with phosphoinositide phosphatase activity which has the capability to 
hydrolyse all seven natural occurring phosphoinositides [18, 19] . We performed a kinetic study of 
these three enzymes in the presence of bpVpic and VO-OHpic to obtain IC50 values using OMFP as 
substrate. As shown in table 3, compound bpVpic inhibits all three tested enzyme with similar 
potency with IC50s in the range of 30 to 40 nM. In contrast VO-OHpic, shows specificity towards 
PTEN with an IC50 of 39.6 ± 2.1 nM. The IC50s for PTP1B is ~20-fold higher and ~13-fold higher 
for SopB as compared to PTEN. Taken all this observations together, VO-OHpic seems to be the 
choice of compounds, if PTEN is to be selectively inhibited, which is in agreement with our earlier 
investigation [11]. 
EDTA has been routinely use in the literature to assay PTP activity as well as probing for reversibility 
of potent inhibitors [20]. Interestingly, if EDTA is included in the assay solution, the inhibition of all 
three tested enzymes by VO-OHpic is fully abolished. EDTA is a known for its strong metal chelating 
characteristics. It is therefore likely, that EDTA chelates the vanadium within the VO-OHpic complex 
thus destroying the VO-OHpic complex. In contrast, the bisperoxovanadium bpVpic seems to 
withstand the presence of EDTA as similar IC50s were obtained with and without EDTA. Since 
EDTA is routinely used in inhibitor screening for PTPs, it is of importance to validate the effect of 
EDTA especially if metal-based compounds are screened, which can affect compound stability and 
activity.  
 
3 Measuring PTEN inhibition in cellulo 
 
One way to measure PTEN inhibition in cellulo is to monitor the status of downstream effectors of 
PTEN-dependent signalling, such as the protein kinase Akt, also known as protein kinase B. Akt 
kinase plays a key role in multiple cellular processes such as glucose metabolism, cell proliferation, 
apoptosis, transcription and cell migration [21]. The activity of Akt is regulated by two 
phosphorylation sites, namely serine 473 (Ser473) and threonine 308 (Thr308). Upon activation of 
PI3 kinase, the phosphoinositide-dependent kinase 1 (PDK1) is translocated to the plasma membrane 
by binding to PI(3,4,5)P3. PDK1, a serine-threonine kinase, phosphorylates Akt in a 
PI(3,4,5)P3dependent manner at Thr308. To become fully activated, Akt requires phosphorylation at 
serine 473 (Ser473), which is phosphorylated by mammalian target of rapamycin complex 2 
(mTORC2) [22]. Through counteracting PI3 kinase, the Akt signalling is terminated by the action of 
PTEN in dephosphorylating PI(3,4,5)P3. Although, the inositol-5-phosphatase SHIP1 and SHIP2 are 
capable of dephosphorylating PI(3,4,5)P3 at the D5 position, it has been shown that PTEN is mainly 
responsible for attenuating PI3 kinase signalling, making Akt phosphorylation a bona fide readout for 
PTEN activity in cellulo [23] .  
 
As can be seen in Figure 1 the phosphorylation levels of Akt at Thr308 as well as Ser473 increases in 
the presence of PTEN inhibitor VO-OHpic.  An activation at a concentration of 50 nM can already be 
detected which is in good agreement with the known in vitro VO-OHpic potency [11, 24], 
demonstrating the good cell permeability of this inhibitor.  The fact that 50 nM of VO-OHpic is 
sufficient to exert cellular effects also means that the chance of hitting other phosphatases can be 
reduced to a minimum as the determined IC50s for other Cx5R phosphatases is at least 10-fold higher 
as shown in table 3.  
In order to detect PTEN dependent activation of Akt, it is crucial to starve cells to bring PI3 kinase 
activity to a very low basal level, without completely blocking it. PI3 kinase generates the substrate 
for PTEN and thus needs to be active, but too much PI3 kinase activity would overshadow the effect 
PTEN inhibition might have on the overall dynamic balance between PI(4,5)P2 and PI(3,4,5)P3. 
Therefore, starved cells are stimulated with a low dose of growth factors in order to activate sufficient 
amounts of PI3 kinase, which in turn will generate small PI(3,4,5)P3 levels that can be removed by the 
PTEN, leaving enough PI(3,4,5)P3 to just activate Akt kinase above the baseline. The dose of growth 
factor (e.g. insulin) needs to be determined prior to experiments on PTEN inhibition in the cellular 
environment. It is important to use a concentration in the low linear phase of a dose-dependent 
activation of Akt kinase, since this will provide the necessary dynamic range to detect changes in Akt 
activation. As shown in figure 1, low insulin will generate a low basal level of Akt activation that can 
be increased by adding the PTEN inhibitor. Whereas high level of insulin (see Figure 2) will result in 
such high cellular levels of PI(3,4,5)P3 that will not be significantly affected by inhibiting PTEN. The 
activation of Akt due to high insulin doses is almost saturated, and thus are not any more limited by 
PTEN’s counteraction against the insulin dependent activation of PI 3kinase. It is therefore of utmost 
importance to determine the concentration of growth factor that generates an Akt kinase activation 
well below the saturation phase. 
 
The activity of PTEN in vivo can also be measured by quantifying cellular PI(3,4,5)P3 levels upon 
treatment with PTEN inhibitors. Lipids can be extracted and then analysed using lipid-binding protein 
domains to detect phosphoinositides [25]. The PLC-δ1 PH domain for example, has been extensively 
used to detect PI(4,5)P2 in fluorescence microscopy techniques either on live or post-fixation cells.  
With respect to PI(3,4,5)P3 binding domains the Akt and GRP1 PH domains are employed the most 
[26]. The GRP1 PH domain is known to be highly specific for PI(3,4,5)P3 whereas the Akt PH 
domain is known to bind PI(3,4)P2 with similar affinity. The GRPH1 PH domain has been used as a 
probe to visualize PtdIns(3,4,5)P3 in cells by live imaging as well as in electron microscopy [27]. 
The amount of cellular PI(3,4,5)P3 levels can be detected using the protein-lipid overlay assay once 
the lipid has been extracted from the cells. Figure 3 shows the result of a protein-lipid overlay assay, 
after treating NIH3T3 with indicated concentrations of VO-OHpic. As shown the amount of 
PI(3,4,5)P3 detected upon treatment with increasing concentration of VO-OHpic is in good agreement 
with the activation level of phospho-Akt (Figure1), making the protein-lipid overlay assay a good 
alternative readout when accessing PTEN inhibition in a cellular environment. There are possibilities 
to use microscopy methods for testing PTEN inhibitors, which would add spatial resolution to the 
general inhibitory data [28]. While the general precautions concerning the basal activation levels of 
Akt phosphorylation (see above) will apply also to any cellular imaging technique, the choice of 
effector being monitored as well as the cell type will have a substantial influence on the optimal 
conditions for monitoring PTEN dependent effects on cellular function.  
The results shown here summarize some recent methodologies and techniques in accessing PTEN 
inhibition by small molecule in vitro and in vivo. Two different PTEN activity assays are described to 
measure PTEN activity/inhibition in vitro using purified enzyme. Each of the two PTEN activity 
assay described here has their advantage. While the PTEN assay with OMFP substrate offers a simple, 
on-line recording assay with high-throughput capability, the malachite green assay employs the 
physiological substrate PI(3,4,5)P3.  In a cellular environment, the inhibitory effect of small molecules 
on PTEN can be measured by detecting downstream effectors of the PTEN signalling, namely by 
detecting the activation of the PI(3,4,5)P3 –dependent protein kinase Akt. Alternatively, the detection 
of changes in cellular PI(3,4,5)P3 levels upon PTEN inhibition by the protein-lipid overlay assay can 
also be employed to measure PTEN inhibition. 
 
4 Experimental procedures for measure PTEN inhibition in vitro and in 
cellulo 
Methods 
 
Materials: 
• Recombinant active PTEN phosphatase (Expressed as GST-fusion in E.coli) 
• Tris-HCl (#93363, Sigma-Aldrich) 
• DL-Dithiothreitol (DTT) (#43815, Sigma-Aldrich) 
• PI(3,4,5)P3, diC16-Na (#208, CellSignals) 
• I(1,3,4,5)P4, (#501, CellSignals) 
• 4-nitrophenyl phosphate (pNPP), (#71768, Sigma-Aldrich) 
• 3-O-Methylfluorescein phosphate (OMFP), (M2629, Sigma Aldrich) 
• 3-O-Methylfluorescein (OMF), (BIM0143, Apollo Scientific) 
• Octyl β-D-glucopyranoside (OG), (#494459, Calbiochem) 
• Malachite Green oxalate salt, (#M6880, Sigma-Aldrich) 
• Ammonium molybdate tetrahydrate, (#09878, Sigma-Aldrich) 
• Bismuth(III) citrate, (#480746, Sigma-Aldrich) 
• Hydrochloric acid 37%, (#320331, Sigma-Aldrich) 
 
4.1 Inhibition assay of PTEN using PI(3,4,5)P3 as substrate 
1. Malachite green dye preparation: A 2x concentrated malachite green reagent is prepared by 
dissolving 5 mM malachite green, 17 mM ammonium heptamolybdate, 77 mM bismuth 
citrate and 1.7 M HCl in distilled water. The mixture is stirred overnight in the dark and 
filtered next day. A calibration curve for inorganic phosphate can be obtained using KH2PO4.  
2. PI(3,4,5)P3 substrate preparation: To prepare a 300 µM(10x stock) substrate solution, PIP3 is 
dissolved in MilliQ grade distilled water with 1% (w/v)  Octyl β-D-glucopyranoside. The 
solution is mixed briefly and sonicated in a bench top bath sonicator for 10 min. After 
sonication, the substrate solution is kept on ice until use. 
3. VO-OHpic inhibitor preparation. For inhibition studies, VO-OHpic is prepared as a 10x stock 
solution in 10% DMSO at concentration ranging between 10 nM to 10 µM. 
4. Enzyme activity of PTEN is measured in 100 mM Tris (pH 7.4) containing 0.5 mM DTT. For 
a 100 µL reaction, 80 µL of the PTEN mixture containing 100 mM Tris and 0.5 mM DTT is 
pre-incubated with 10 µL of the 10x stock solution of VO-OHpic into a 96-well plate. For the 
control reaction. Pre-incubate at room temperature for 10min. After 10 min, add 10 µL of the 
10x substrate stock solution to the control and reaction wells. Incubate the reaction for 20min 
at 37°C. 
5. After reaction time, stop the reaction by adding 100 µL of malachite green dye to the reaction 
and the control well. Add 80 µL of PTEN mixture to the control well. Let the dye to develop 
for 10 min at room temperature.  Read the absorbance at 625 nm. 
6. Calculate the PTEN activity by subtracting the relevant blanks. 
7. Use standard curves to transform activities from OD units to molar turnover. 
 
4.2 PTEN inhibition assay with OMFP as substrate 
1. OMFP substrate preparation: The cyclohexylammonium salt of 3-O-Methylfluorescein 
phosphate (OMFP) is dissolved in DMSO to a concentration of 20 mM. Sonication might be 
required to accelerate the process. DMSO stock solutions of OMFP can be stored at -20°C in 
the dark. For inhibition assays, a 10x stock solution is prepared by diluting OMFP to a 
concentration of 2 mM containing 10% DMSO. 
2. The enzyme activity of PTEN is measured in 100 mM Tris (pH 7.4) containing 0.5 mM DTT. 
For a 100 µL reaction, 80 µL of the PTEN mixture containing 100 mM Tris and 0.5 mM DTT 
is pre-incubated at room temperature with 10 µL of the 10x stock solution of PTEN inhibitor 
using a 96-well plate. After 10 min, reactions were initialised by adding 10 µL of the 10x 
substrate stock solution (OMFP) to the PTEN-buffer mixture. The conversion of OMFP to 
OMF by PTEN will cause a corresponding change in fluorescence units (FU) in the 96-well 
microtiter plate (excitation at 485 nm and emission at 525 nm), which can be used to monitor 
PTEN activity continuously. 
 
4.3 Cellular PTEN inhibition assay 
Materials 
 
1. Cell line: NIH 3T3 mouse fibroblasts (or other PTEN expressing cell lines) 
2. Dulbecco’s Modified Eagle’s Medium, high glucose (DMEM) (D5671, Sigma-Aldrich) 
supplemented with 10% newborn calf serum (ATCC) 
3. Dulbecco’s Modified Eagle’s Medium, low glucose (DMEM) (D6046, Sigma-Aldrich)  
4. Phosphate buffer saline (PBS) (Gibco, Life Technologies) 
5. Trypsin-EDTA solution (T4174, Sigma-Aldrich) 
6. Insulin (I6634, Sigma-Aldrich). Prepare a 1mg/mL solution in 0.02 M HCl, filter-sterilised 
and store in aliquots at -20°C. 
7. PTEN inhibitor VO-OHpic at final concentration ranging between 50 nM and 1 µM. 
8. 1 x SDS sample buffer: 62.5 mM Tris-HCl pH 6.8, 2.5 % SDS, 0.002 % Bromophenol Blue, 
5% β-mercaptoethanol, 10 % glycerol  
9. Phospho-Akt (Ser473) antibody (Cell Signaling) 
10. Phospho-Akt (Thr308) antibody (Cell Signaling) 
11. Akt antibody (Cell Signaling) 
12. Tris-buffered saline with 0.1% Tween 20 (TBST): 20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% 
Tween 20 (v/v). 
 
Method 
1. NIH 3T3 mouse fibroblast are grown in DMEM, high glucose with 10% newborn calf serum 
and passaged when required (around 80-90% confluency) using trypsin/EDTA to maintain 
cultures. For PTEN inhibition experiment passage cells 1 in 10 into 60 mm dishes. Grow cells 
until 70-80% confluency. 
2. Wash cells twice with PBS and starved in low glucose DMEM without serum for 16 hours. 
3. After starvation, wash dishes with PBS and add fresh starvation medium. 
4. Add PTEN inhibitor and solvent control to dishes and incubate in a CO2 incubator for 30 min. 
5. Add insulin to a final concentration of 0.02 µg/mL and incubate for 10 min. 
6. Remove media and wash cells twice with ice-cold PBS. 
7. Add 300 µL of 1x SDS lysis buffer to each dish and scrape cells of into a 1.5 mL centrifuge 
tube. 
8. Boil sample 94°C for 5 min and cool on ice. 
9. Run SDS gel electrophoresis and transfer the protein onto a nitrocellulose membrane 
according to manufacturer’s instructions. 
10. Block the membrane using a 5% milk powder solution in TBST for 1 hour at room 
temperature. 
11. Wash the membrane twice with TBST for 5 min each. 
12. Incubate the membrane with a 1:1000 dilution of phospho-Akt antibody or pan-Akt antibody 
in TBST containing 5% BSA at 4°C for 16 hours. 
13. Wash membrane 3 times for 10 min with TBST. 
14. Incubate membrane with appropriate secondary antibody according to manufacturer’s 
instructions. 
15. Wash as in step 13. Visualise western blot using ECL solution according to manufacture 
specification. 
 
4.4 Protein-lipid overlay assay for detecting cellular PI(3,4,5)P3 levels upon PTEN 
inhibition 
Materials 
 
1. Cell line: NIH 3T3 mouse fibroblasts (or other PTEN expressing cell lines) 
2. Dulbecco’s Modified Eagle’s Medium, high glucose (DMEM) (D5671, Sigma-Aldrich) 
supplemented with 10% newborn calf serum (ATCC) 
3. Dulbecco’s Modified Eagle’s Medium, low glucose (DMEM) (D6046, Sigma-Aldrich)  
4. Phosphate buffer saline (PBS) (Gibco, Life Technologies) 
5. Trypsin-EDTA solution (T4174, Sigma-Aldrich) 
6. Insulin (I6634, Sigma-Aldrich). Prepare a 1mg/mL solution in 0.02 M HCl, filter-sterilised 
and store in aliquots at -20°C. 
7. PTEN inhibitor VO-OHpic 
8. Recombinant GRP1 PH domain (Expressed as GST-fusion protein in our laboratory) 
9. Anti-GST HRP conjugated antibody 
10. ECL reagent or similar 
11. Hybond-C extra nitrocellulose membrane (GE Healthcare) 
12. Chloroform 
13. Methanol 
 
Methods 
1. NIH 3T3 mouse fibroblast are grown in DMEM, high glucose with 10% newborn calf serum 
and passaged when required (around 80-90% confluency) using trypsin/EDTA to maintain 
cultures. For PTEN inhibition experiment passage cells 1 in 10 into 100 mm dishes. Grow 
cells until 70-80% confluency. 
2. Wash cells twice with PBS and starved in low glucose DMEM without serum for 16 hours. 
3. After starvation, wash dishes with PBS and add fresh starvation medium. 
4. Add PTEN inhibitor and solvent control to dishes and incubate  
5. Add insulin to a final concentration of 0.05 µg/mL and incubate in a CO2 incubator for 30 
min. 
6. Remove media and wash cells twice with ice-cold PBS. 
7. Add 5 mL of 0.5 M ice-cold TCA to the dish and scrape cells of into a 15 mL centrifuge tube. 
8. Centrifuge sample at 1500 rpm for 10 min and discard the supernatant. 
9. Wash the pellet with 2 mL of 5% TCA/ 1 mM EDTA. Centrifuge at 1500 RPM for 10 min 
and discard the supernatant. 
10. To extract PIP3 add 750 µL of Methanol:Chloroform:H2O (80:40:1) and incubate at room 
temperature for 15min. Vortex in between. 
11. Centrifuge for 10 min at 1500 rpm and transfer supernatant in a 1.5 mL centrifuge tube. 
12. Add 250 µL of Chloroform and 450 of 0.1 M HCl to induce phase split. Incubate sample for 
10 min at room temperature and vortex every 2 min. Centrifuge at 1500 rpm for 10 min and 
collect lower phase into a new centrifuge tube. Dry down lipids and re-suspend into 20 µL of 
a solution of  methanol:chloroform:water (2:1:0.8) and vortex briefly. 
13. Spot a total of 5 µL of lipid extracts for every studied condition onto a Hybond C 
nitrocellulose membrane. Spot 1 µL at a time, let the membrane dry and add another 1 µL up 
to a total of 5 µL. 
14. Let the membrane dry at room temperature for 1 hour. 
15. Block the membrane with 2mg/mL of fatty acid free BSA in TBST for 1 hour at room 
temperature. 
16. Incubate the membrane with 10-50 nM of GRPH1 PH domain for 16 hours at 4°C in blocking 
buffer. 
17. Wash the membrane 5 times 10min with TBST. 
18. Incubate the membrane with a 1:5000 dilution of anti-GST-HRP conjugated antibody for 1 
hour at room temperature in blocking buffer. 
19. Wash as in 17. 
20. Visualise the membrane using ECL reagent and chemiluminescence reader. 
 
 
 
Figure captions 
Figure 1 NIH 3T3 cells were starved overnight, incubated with indicated concentration of VO-
OHpic for 30 min, followed by insulin stimulation as indicated. Cells were collected and analysed by 
western blotting using phospho-Akt (Thr308 and Ser473) and total Akt antibodies. The blot in Figure 
1 (top panel) is representative of two independent repeats. The resulting blot intensities were 
quantified using ImageJ where high insulin stimulation (10 µg/mL) was set to 100% (bottom panel). 
Error bars shown are the standard error from the two independent experiments. 
 
 
Figure 2 NIH 3T3 cells were starved overnight, incubated with indicated concentration of VO-
OHpic for 30 min, followed by insulin stimulation as indicated. Cells were collected and analysed by 
western blotting using phospho-Akt (Thr308 and Ser473) and total Akt antibodies. The blot in Figure 
1A was quantified using ImageJ (http://imagej.nih.gov/ij/) where high insulin stimulation (10 µg/mL) 
was set to 100%. Blot shown is representative of two independent experiment. 
 
Figure 3 Protein-lipid Overlay assay to detect PI(3,4,5)P3 from VO-OHpic treated NIH3T3 
cells. NIH 3T3 cells were starved for 16 hours and then treated with VO-OHpic at concentration as 
indicated. Cells were stimulated with 0.05 µg/mL insulin for 30 min. Lipids were extracted and 
detected with GST-tagged GRP1 domain. Blot shown is representative of three independent 
experiment. 
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Tables: 
 
Compound Dose  Cell tissue/Organ Effect upon PTEN inhibition Ref 
bpV(phen) 0.4 µmol/mouse C57BL/6 Mice Increased lung tissue levels of phospho-Akt and ERK [29] 
bpV(pic) 5 µM Skin-derived precursors 
Enhancing the PI3K-Akt path-
way through PTEN inhibition 
improved self-renewal of human 
foreskin 
[30] 
bpV(pic) 20µg/100 g Wistar rats 
Prevents ischemic brain injury by 
activating the mTOR signaling 
pathway 
[31] 
bpV(pic) 2mg/1000g Wistar rats Attenuation of hippocampal apoptosis [32] 
bpV(pic) 10 – 90 nM SH-SY5Y  cells Reduction of okadaic  acid-induced  tau phosphorylation   [33] 
bpV(pic) 200 µg/kg Adult  female  Sprague-Dawley  rats 
Injury-induced  neuronal  soma  
atrophy  was  reversed  by  PTEN 
inhibition 
[34] 
bpV(OHpic) 1 µM Neonatal mouse ovaries 
Demonstrated the use of PTEN 
inhibitor to generate mature 
human oocytes for use in novel 
IVF techniques 
[35] 
bpV(OHpic) 1 µM Ovarian cortical tissue 
Affects human ovarian follicle 
development by promoting the 
initiation of folliclegrowth and 
development to the secondary 
stage 
[36] 
VO-OHpic 500 nM Human xenograft Induced senescence and inhibits tumorigenesis in vivo [15] 
VO-OHpic 500 nM Carcinoid cell line BON Decreased secretion and synthesis of serotonin [37] 
VO-OHpic 100 nM Mouse adrenal chromaffin cells 
Abolished the effect of compound 
IC87114, a potent inhibitor of 
PI3Kδ in promoting potentiation 
of Ca2 + 
-stimulated catecholamine release 
[38] 
VO-OHpic  10 µg/kg Mice Induced cardioprotection against ischemia–reperfusion injury [39] 
VO-OHpic 500nM Breast cancer cells MDA-MB-231 
Abolished the 
effect of PI3 kinase inhibitor 
IC87114 on Akt inhibition 
[40] 
VO-OHpic 0.1-5µM Mouse ventricular cardiomyocytes 
Highly protective against cell 
death induced by ischemia and 
reperfusion 
[41] 
 Table 1: Recent applications of vanadium-based PTEN inhibitors in cellulo and in vivo. 
 
 
 
 
 
 
Substrate KM (µM) 
Vmax 
(nmoles*mg-1*min-1) 
PI(3,4,5)P3 30 ± 4 47.5 ±  1.8 
I(1,3,4,5)P4 88 ± 9 9.1 ± 0.4 
pNPP 25600 [16] - 
OMFP 216 ± 14 0.4 ± 0.1 
 
Table 2: Kinetic parameters of PTEN phosphatase activity measured with various substrates. Please 
refer to methods section for experimental details. 
 
 
 PTP1B 
bpVpic 
PTP1B 
VO-
OHpic 
PTEN 
bpVpic 
PTEN 
VO-
OHpic 
SopB 
bpVpic 
SopB 
VO-
OHpic 
HEPES 37.5 ± 1.6 790.3 ± 
41.8 
29.3 ± 3.1 39.6 ± 
2.1 
42.3 ± 6.2 513.6 
±3.2 
HEPES/EDTA 60.5 ± 2.2 > 20000 36.3 ± 4.3 > 20000 50.3 ±5.3 > 20000 
 
Table 3. IC50 values (nM) of PTEN, PTP1B and SopB inhibition by vanadium inhibitors bpVpic and 
VO-OHpic. Assays were performed using OMFP as substrate (see methods). The values shown are 
the mean ± standard deviation of three independent experiments.  
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